Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. District Court for the District of New
Jersey has ruled in Merck's favor in two jointly related patent
infringement suits against Mylan Pharmaceuticals Inc.
"The court appropriately ruled that the patent for ZETIA and VYTORIN in
the U.S. is valid and enforceable," said Bruce N. Kuhlik, executive vice
president and general counsel of Merck. The patent at issue in this
trial is RE 42,461 which covers ezetimibe, an active ingredient in both
ZETIA and VYTORIN and expires April 2017.
In its decision, the court upheld Merck's patent on ZETIA and VYTORIN
and ruled that the patent was valid and enforceable. Mylan had admitted
that its product would infringe the patent. The court also issued an
injunction blocking the approval of Mylan's generic versions until the
expiration of the patent.
Mylan had been seeking U.S. Food and Drug Administration (FDA) approval
to sell generic versions of ZETIA and VYTORIN. In December 2009, Merck
filed the lawsuit against Mylan in respect of Mylan’s application to the
FDA seeking pre-patent expiry approval to sell a generic version of
VYTORIN and in June 2010, Merck filed a separate lawsuit against Mylan
in respect of Mylan's application seeking pre-patent approval to sell a
generic version of ZETIA.
Judge Jose Linares presided over the trial. Merck was represented by
Sidley Austin LLP, Lowenstein Sandler PC and Robinson, Wettre & Miller
LLC.
About Merck
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter, Facebook and YouTube.
Forward-Looking Statement
This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company’s plans, objectives,
expectations and intentions and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks
and uncertainties. Actual results may differ from those set forth in the
forward-looking statements.
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that all of the expected synergies from the merger of Merck
and Schering-Plough will not be realized, or will not be realized within
the expected time period; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; Merck’s ability to accurately predict future market
conditions; dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to litigation
and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2011 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).
